Developing therapeutic antibodies for Alzheimer's disease

项目概要/摘要 数以百万计的美国人患有阿尔茨海默氏症，目前还没有治疗方法可用于 预防或减缓疾病的进展。阿尔茨海默病患者未得到满足的医疗需求 导致美国每年有数千亿美元的有偿和无偿的医疗费用。 VersaPeutics是一家开发阿尔茨海默病新疗法的小企业。在本阶段I SBIR中， 我们将进行临床前研究，以确定基于抗体的治疗方法的可行性， 设计用于治疗阿尔茨海默病，使用独特的作用机制，通过检查药代动力学， 有效性、毒性和毒代动力学。在这些研究结束时，我们将遇到几个重要的 这些里程碑将支持我们治疗阿尔茨海默病的新疗法的进一步临床前开发。

PROJECT SUMMARY/ABSTRACT Millions of Americans suffer from Alzheimer’s disease and there are currently no therapies available to prevent or slow the progression of the disease. The unmet medical needs of individuals with Alzheimer’s disease result in hundreds of billions of dollars of costs in paid and unpaid caregiving in the United States every year. VersaPeutics is a small business developing novel therapeutics for Alzheimer’s disease. In this Phase I SBIR project we will perform preclinical studies to determine the feasibility of antibody-based therapeutics that are designed to treat Alzheimer’s disease using a unique mechanism of action, by examining pharmacokinetics, efficacy, toxicity and toxicokinetic. At the conclusion of these studies, we will have met several important milestones that will support further preclinical development of our novel therapeutics for Alzheimer’s disease.